reported that cetuximab, an EGFR‐specific mAb, significantly decreased PMN‐MDSCs only in responders among patients with head and neck squamous cell carcinoma (HNSCC); meanwhile, it can inhibit the polarization of monocytes into M2 macrophages and induce functioning by bonding Fc‐gamma receptors in myeloid cells. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.